Hypothalamic-pituitary-adrenal system, neurotrophic factors and clozapine response: association with FKBP5 and NTRK2 genes
- PMID: 25751398
- DOI: 10.1097/FPC.0000000000000132
Hypothalamic-pituitary-adrenal system, neurotrophic factors and clozapine response: association with FKBP5 and NTRK2 genes
Abstract
Clozapine is an atypical antipsychotic drug known as being more effective compared with traditional antipsychotics for patients with poor response or resistance to treatment. It has been demonstrated that clozapine modulates hypothalamic-pituitary-adrenal activity and affects central brain-derived neurotrophic factor levels, which could explain part of its therapeutic efficacy. In this study, we investigated the role of genes related to the hypothalamic-pituitary-adrenal axis (FKBP5 and NR3C1) and neurotrophic factors (BDNF and NTRK2) in clinical response to clozapine in 591 schizophrenia patients. We found significant allelic and genotype associations between FKBP5-rs1360780, NTRK2-rs1778929 and NTRK2-rs10465180 polymorphisms and clozapine response. The haplotypes composed of rs1360780-rs3777747-rs17542466-rs2766533 (FKBP5) and rs1619120-rs1778929-rs10465180 (NTRK2) were also nominally significant. Our results suggest that genetic variability in FKBP5 and NTRK2 genes may partially explain clinical response to clozapine. Further studies are needed to clarify the involvement of these genes in clinical response to atypical antipsychotics.
Similar articles
-
Clozapine pharmacogenomics: a review of efficacy, pharmacokinetics, and agranulocytosis.Curr Opin Psychiatry. 2018 Sep;31(5):403-408. doi: 10.1097/YCO.0000000000000440. Curr Opin Psychiatry. 2018. PMID: 29985178 Review.
-
Effect of the common functional FKBP5 variant (rs1360780) on the hypothalamic-pituitary-adrenal axis and peripheral blood gene expression.Psychoneuroendocrinology. 2014 Apr;42:89-97. doi: 10.1016/j.psyneuen.2014.01.007. Epub 2014 Jan 23. Psychoneuroendocrinology. 2014. PMID: 24636505
-
Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia.Pharmacogenet Genomics. 2010 Apr;20(4):274-6. doi: 10.1097/FPC.0b013e328337ce3e. Pharmacogenet Genomics. 2010. PMID: 20168265
-
Genetic association of the transcription of neuroplasticity-related genes and variation in stress-coping style.Brain Behav. 2015 Sep;5(9):e00360. doi: 10.1002/brb3.360. Epub 2015 Jun 24. Brain Behav. 2015. PMID: 26445699 Free PMC article.
-
Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine.Biol Psychiatry. 2000 Feb 1;47(3):252-66. doi: 10.1016/s0006-3223(99)00298-x. Biol Psychiatry. 2000. PMID: 10682223 Review.
Cited by
-
Clinical Utility and Implementation of Pharmacogenomics for the Personalisation of Antipsychotic Treatments.Pharmaceutics. 2024 Feb 7;16(2):244. doi: 10.3390/pharmaceutics16020244. Pharmaceutics. 2024. PMID: 38399298 Free PMC article. Review.
-
Role of FKBP5 and its genetic mutations in stress-induced psychiatric disorders: an opportunity for drug discovery.Front Psychiatry. 2023 Jun 16;14:1182345. doi: 10.3389/fpsyt.2023.1182345. eCollection 2023. Front Psychiatry. 2023. PMID: 37398599 Free PMC article. Review.
-
Peripheral biomarkers of treatment-resistant schizophrenia: Genetic, inflammation and stress perspectives.Front Pharmacol. 2022 Oct 12;13:1005702. doi: 10.3389/fphar.2022.1005702. eCollection 2022. Front Pharmacol. 2022. PMID: 36313375 Free PMC article. Review.
-
The Impact of the FKBP5 Gene Polymorphisms on the Relationship between Traumatic Life Events and Psychotic-Like Experiences in Non-Clinical Adults.Brain Sci. 2021 Apr 28;11(5):561. doi: 10.3390/brainsci11050561. Brain Sci. 2021. PMID: 33925151 Free PMC article.
-
Second-Generation Antipsychotics and Dysregulation of Glucose Metabolism: Beyond Weight Gain.Cells. 2019 Oct 29;8(11):1336. doi: 10.3390/cells8111336. Cells. 2019. PMID: 31671770 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Miscellaneous
